mRNA Vaccines and Therapeutics Industry Forecast to Generate Over $72 Billion in Revenues by 2032 - Breakdown by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-user, and Region
Portfolio Pulse from
The mRNA vaccines and therapeutics industry is projected to generate over $72 billion in revenues by 2032, driven by the growing incidence of chronic and infectious diseases, advancements in synthetic biology and bioinformatics, and rising demand for personalized medicine.
December 11, 2024 | 9:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna, a key player in the mRNA industry, is likely to benefit from the projected $72 billion revenue in the mRNA vaccines and therapeutics market by 2032.
Moderna is a leading company in the mRNA space, and the industry's growth to $72 billion by 2032 suggests increased demand for its products, likely boosting its revenues and stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80